Liposomal doxorubicin is active against AIDS-related Kaposi's sarcoma

Drugs and Therapy Perspectives

Volumn 9, Issue 12, 1997, Pages 1-5

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW SUPPRESSION; COMBINATION CHEMOTHERAPY; DRUG FORMULATION; HUMAN; HYPERSENSITIVITY REACTION; KAPOSI SARCOMA; SHORT SURVEY; STOMATITIS; TOXICITY TESTING;

EID: 0030835317     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-199709120-00001     Document Type: Short Survey

References (15)

1. Wang C-YE, Schroeter AL, Su, WPD. Acquired immunodeficiency syndrome-related Kaposi's sarcoma. Mayo Clinic Proc 1995; 70: 869-79
2. Harrison M, Harrington KJ, Stewart JSW. Liposomal chemotherapy for AIDS-related Kaposi's sarcoma. Expert Opin Invest Drug 1995 Dec; 4: 1197-203
3. Lilenbaum RC, Ratner L. Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 1994 Feb; 8: 141-51
4. Coukell AJ, Spencer CM. Liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of patients with AIDS-related Kaposi's sarcoma. Drugs 1997; 53 (3): 520-538
5. Volm MD, Von Roenn JH. Treatment strategies for epidemic Kaposi's sarcoma. Current Opinion Oncology 1995; 7: 429-36
6. Northfelt DW. Treatment of Kaposi's sarcoma: current guidelines and future perspectives. Drugs 1994 Oct; 48: 569-82
7. Northfelt DW, Dezube B, Miller B, et al. Randomized comparative trial of Doxil vs. Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma (AIDS-KS) [abstract no. 1515]. Blood 1995; 86 (10) Suppl. 1: 382a
8. Goebel F-D, Goldstein D, Goos M, et al. Efficacy and safety of Stealth® liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 1996 Apr; 73: 989-94
9. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995 Apr; 13 (4): 914-20
10. British National Formulary No. 32. London: The Pharmaceutical Press, 1996 Sep: 356-9
11. 1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997: II-261, II-738-42
12. SEQUUS Pharmaceuticals Inc. Doxil® prescribing information. Menlo Park, California, USA, 1995
13. rd ed. Montvale NJ: Medical Economics, 1997: 1102
14. Bielack SS, Erttmann R, Kempf-Bielack B, et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996; 32A: 1652-60
15. Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of DOXIL (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin [abstract no. 843]. Proc Am Soc Clin Oncol 1996; 15: 303